Anavex Life Sciences Announces Publication of Foundational Data for ANAVEX®2-73 (blarcamesine) in Rett Syndrome

Anavex Life Sciences Announces Publication of Foundational Data for ANAVEX®2-73 (blarcamesine) in Rett Syndrome  Published in Pharmacology Biochemistry and Behavior, Results Highlight Improvements in Multiple Motor, Sensory, and Autonomic Phenotypes Associated with Rett Syndrome Study Provided Proof-of-Concept for Ongoing ANAVEX®2-73 (blarcamesine) Phase 2 Trials NEW YORK – November 6, 2019 – Anavex Life Sciences Corp.…